APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma of the prostate

  * Any T, any N, M0
* Received prior therapy comprising one of the following regimens for primary prostate cancer:

  * External beam radiotherapy
  * Brachytherapy with or without pelvic external beam radiotherapy
  * Cryosurgery
  * Radical prostatectomy with or without adjuvant or salvage radiotherapy

    * Adjuvant or salvage radiotherapy after radical prostatectomy is allowed provided the following criteria is met:

      * PSA was never greater than 6.0 ng/mL
      * At least 3 months since androgen deprivation
* Elevated PSA (0.4-6.0 ng/mL) that has increased on 2 measurements taken at least 2 weeks apart
* No history of or radiological evidence of current CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, or brain metastases)

PATIENT CHARACTERISTICS:

Performance status:

* ECOG 0-1

Life expectancy:

* At least 12 months

Hematopoietic:

* WBC greater than 2,500/mm\^3
* Absolute neutrophil count greater than 1,000/mm\^3
* Platelet count greater than 100,000/mm\^3
* No prior bleeding disorder

Hepatic:

* Bilirubin no greater than 2 times upper limit of normal (ULN)
* AST no greater than 2 times ULN
* Hepatitis B and C negative

Renal:

* Creatinine no greater than 2 times ULN
* BUN no greater than 2 times ULN

Cardiovascular:

* No clinically significant cardiovascular disease
* No New York Heart Association grade II-IV heart disease (symptomatic congestive heart failure)
* No unstable angina pectoris
* No serious cardiac arrhythmia requiring medication
* No uncontrolled hypertension
* No prior myocardial infarction
* No grade II or greater peripheral vascular disease within the past year
* No prior deep vein thrombosis

Other:

* Fertile patients must use effective contraception
* HIV and HTLV I and II negative
* No other uncontrolled illness, underlying medical condition, psychiatric illness, or social situation that would preclude study participation
* No ongoing or active infection
* No active autoimmune disease requiring treatment
* No significant traumatic injury within the past 4 weeks
* No serious nonhealing wound, ulcer, or bone fracture
* No other "currently active" malignancy except nonmelanoma skin cancer

  * Not "currently active" if considered by physician as having less than 30% risk of relapse after completion of therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior immunotherapy
* No prior anti-vascular endothelial growth factor therapy

Chemotherapy:

* No prior chemotherapy

Endocrine therapy:

* No prior hormonal therapy (e.g., luteinizing hormone-releasing hormone \[LHRH\] agonists or antagonists, antiandrogens, estrogens, megestrol, or PC-SPES) for progressive disease
* Prior hormonal therapy in adjuvant or neoadjuvant setting as primary therapy allowed if at least 3 months since androgen deprivation
* No concurrent systemic steroid therapy (inhaled or topical steroids allowed)

Radiotherapy:

* No concurrent radiotherapy

Surgery:

* At least 4 weeks since prior major surgery, including open biopsy or needle biopsy of liver
* No concurrent major surgery

Other:

* At least 10 days since prior aspirin
* At least 10 days since prior oral or parenteral anticoagulants except to maintain patency of pre-existing permanent indwelling IV catheters
* No concurrent aspirin
* No concurrent oral or parenteral anticoagulants except to maintain patency of pre-existing permanent indwelling IV catheters
* No other concurrent experimental or commercial agents or therapies for prostate cancer